- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01411085
Risperidone and Desipramine in Alcohol Use and Schizophrenia (RADIAUS)
Alcoholism and Schizophrenia: A Translational Approach to Treatment
Note: In June 2013, the study design was changed from a randomized controlled study of risperidone + despiramine vs. risperidone vs. placebo to an open label pre-post study of risperidone (or risperidone-like drug) + desipramine. The aims of the study were revised to read:
- To determine whether participants treated with risperidone in combination with desiprmaine have less alcohol use (fewer drinking days; fewer heavy drinking days) during the final 8 weeks on these medications as compared to pre-baseline. The primary hypothesis is that compared to pre-baseline, participants will demonstrate fewer days of drinking (per week), as well as fewer days of heavy drinking (per week) in the final eight weeks they are taking risperidone and desipramine, as recorded on the Timeline Follow-Back assessment
- To explore changes in symptoms (of schizophrenia and of depression) in the final eight weeks of treatment with risperidone + desipramine compared to the period before baseline
- To assess the side effect burden associated with the combination of these two medications in participants.
The original aims of the study were:
The purpose of this study is to determine whether participants who are treated with risperidone in combination with desipramine have less alcohol use (fewer drinking days; fewer heavy drinking days) than do participants who are treated with RISP with placebo. The primary hypothesis is that compared to treatment with risperidone, participants randomized to a combination of risperidone plus desipramine will have fewer days of drinking, as well as fewer days of heavy drinking. The study will also compare the effects of risperidone as compared to risperidone plus desipramine on participants' symptoms and side effects.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Alcohol use disorder is at least three times more common in schizophrenia than in the general population, and worsens the course of schizophrenia. Typical antipsychotic agents are of limited value in controlling alcohol use in these "dual diagnosis" patients. Data from our group and others suggest that the atypical antipsychotic drug clozapine limits alcohol and cannabis use in "dual diagnosis" patients with schizophrenia much more effectively than other antipsychotics that have been assessed, however, the side effects produced by clozapine severely limit its use.
The investigators have hypothesized that clozapine will lessen alcohol/substance use in such dual diagnosis patients in part because of its mechanism of action that includes release of dopamine (DA) in the prefrontal cortex which will help to normalize dysfunctional brain reward circuits that may underlie the co- occurring alcohol/substance use in patients with schizophrenia. Our data suggest that the effect of clozapine can be duplicated in rodents when medications with clozapine-like activity (DA D2 antagonism, potent norepinephrine (NE) α2 receptor antagonism and NE reuptake inhibition) are combined together. The investigators have demonstrated that RISP (a medication that is both a DA D2 receptor antagonist, and a potent NE α2 receptor antagonist), in combination with the specific NE reuptake inhibitor desipramine, significantly decreases alcohol consumption in alcohol drinking rodents.
This translational study is a pilot "proof of concept" 14-week double-blind investigation of participants who have co-occurring diagnoses of schizophrenia and an alcohol use disorder. Patients not treated with risperidone (or a risperidone-like agent, including risperidone long-acting, paliperidone and paliperidone palmitate) at the time of consent will be switched to oral risperidone in the first two weeks of the study. At Week 3, all participants will begin treatment with risperidone risperidone plus desipramine and followed for 12 weeks. The primary outcome measure will be days of drinking (per week), as well as days of heavy drinking (per week). The investigators anticipate that data from this study will support a larger trial of risperidone + desipramine in patients with schizophrenia and an alcohol use disorder.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01605
- University of Massachusetts Medical School
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Michigan State University / Cherry Street Health Services
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth Medical School
-
-
South Carolina
-
Columbia, South Carolina, United States, 29203
- University of South Carolina School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Meets the diagnostic criteria of schizophrenia or schizoaffective disorder
- Meets the diagnostic criteria for a current alcohol use disorder (abuse or dependence)
- Recent alcohol use as documented on the Timeline Followback
- Receives outpatient treatment with oral antipsychotic medication (including risperidone.
- Is willing to switch to risperidone treatment at the beginning of the study.
Exclusion Criteria:
- Other substance use disorder other than alcohol, caffeine and nicotine, and cannabis abuse, as defined by DSM-IV criteria.
- Receives current treatment with Clozapine
- Continues to use alcohol despite current adequate treatment with medication to decrease alcohol use(e.g. naltrexone, acamprosate, disulfiram or topiramate)
- Is determined to be a "slow metabolizer" of CYP2D6
- Is currently pregnant, trying to become pregnant, or nursing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Risperidone + Desipramine
All participants will be treated with risperidone (or a risperidone-like agent including: risperidone long-acting, paliperdione, and paliperidone palmitate) at the time treatment with desipramine is initiated.
The target dose of oral risperidone is 4mg though variations are allowed.
The target dose of desipramine is 100mg.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Timeline Followback Assessing Number of Drinks Per Week
Time Frame: Weekly for 14 weeks, using data from last 8 weeks
|
Alcohol/other substance use (including tobacco) will be assessed primarily by weekly self-report using the Timeline Followback (TLFB) method enhanced by procedures to strengthen the reliability and validity of this measure.
It involves asking participants to retrospectively estimate their alcohol and other substance use.
|
Weekly for 14 weeks, using data from last 8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Alan I Green, MD, Dartmouth-Hitchcock Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Pathologic Processes
- Alcohol-Related Disorders
- Substance-Related Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Alcoholism
- Schizophrenia
- Disease
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Antidepressive Agents, Tricyclic
- Adrenergic Uptake Inhibitors
- Risperidone
- Desipramine
Other Study ID Numbers
- 1R21AA019534-01A1 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcoholism
-
Yale UniversityCompletedFamilial Alcoholism VulnerabilityUnited States
-
Yonsei UniversityTerminated
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingFamilial Alcoholism VulnerabilityUnited States
-
University of Southern DenmarkActive, not recruitingGeneral Practice | Alcohol Abuse Alcoholism | Screening and Brief InterventionDenmark
-
University of FloridaNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedEffects of Family History of Alcoholism and Sex on Alcohol AnalgesiaUnited States
-
Brown UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcoholic Liver Disease | Alcoholism,United States
-
Khoo Teck Puat HospitalNot yet recruitingEmergencies | Alcohol Use Disorder | Alcoholism and Alcohol Abuse
-
National Institute on Drug Abuse (NIDA)The Peter G. Dodge Foundation (PGDF)Completed
-
Virginia Commonwealth UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Yale University; University...CompletedAlcoholismUnited States
-
University of Sao PauloCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsEnrolling by invitation
Clinical Trials on Risperidone + Desipramine
-
SandozCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Rovi Pharmaceuticals LaboratoriesCompletedAcute SchizophreniaUnited States, Ukraine
-
Joel NealTerminatedNeuroendocrine Tumors | Small Cell Lung Cancer (SCLC)United States
-
Boehringer IngelheimCompleted
-
Northwestern UniversityOrtho-McNeil Janssen Scientific Affairs, LLCCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Rovi Pharmaceuticals LaboratoriesCompletedSchizophrenia | Schizoaffective DisorderSpain, South Africa, Russian Federation, Croatia
-
Zogenix, Inc.CompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Zogenix, Inc.Completed
-
Janssen-Cilag S.p.A.CompletedSchizophrenia | Schizoaffective Disorder